BEIJING, Dec. 29, 2017 /PRNewswire/ -- Sinovac Biotech
Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical
products in China, announced today
that it will hold its 2017 Annual Meeting of Shareholders on
Tuesday, February 6, 2018 at
9:00 a.m. Beijing Time. The meeting
will be held at No. 39 Shangdi Xi Road, Haidian District,
Beijing, PRC. All shareholders of
record as of December 26, 2017 will
be eligible to vote and are invited to attend.
The primary agenda of the meeting is to approve the re-election
of Weidong Yin, Yuk Lam Lo, Simon
Anderson, Kenneth Lee and
Meng Mei as the Company's directors
with a term expiring at the next annual meeting of shareholders and
until their successors are duly elected; approve the audited
consolidated financial statements of the Company for the financial
year ended December 31, 2016 together
with the Report of Independent Registered Public Accounting Firm
thereon and the notes thereto; approve the appointment of Ernst
& Young Hua Ming LLP as our independent auditor for the fiscal
year ending December 31, 2017 and to
authorize the directors of the Company to fix such independent
auditor's remuneration.
Sinovac's 2016 annual report and proxy statements, including the
Notice of the 2016 Annual General Meeting, are available on the
Company's website: http://www.sinovac.com/?optionid=751
Shareholders of the Company may receive a hard copy of 20-F free
of charge upon request. Such request can be made by sending an
e-mail to ir@sinovac.com, along with complete contact details and a
mailing address.
About Sinovac.
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that
focuses on the research, development, manufacturing and
commercialization of vaccines that protect against human infectious
diseases. Sinovac's product portfolio includes vaccines against
enterovirus71, or EV71, hepatitis A and B, seasonal influenza, H5N1
pandemic influenza (avian flu), H1N1 influenza (swine flu), and
mumps. The EV71 vaccine, an innovative vaccine developed by Sinovac
against hand foot and mouth disease caused by EV71, was
commercialized in China in 2016.
In 2009, Sinovac was the first company worldwide to receive
approval for its H1N1 influenza vaccine, which it has supplied to
the Chinese Government's vaccination campaign and stockpiling
program. The Company is also the only supplier of the H5N1 pandemic
influenza vaccine to the government stockpiling program. The
Company is developing a number of new products including a
Sabin-strain inactivated polio vaccine, pneumococcal
polysaccharides vaccine, pneumococcal conjugate vaccine and
varicella vaccine. Sinovac primarily sells its vaccines in
China, while also exploring growth
opportunities in international markets. The Company has exported
select vaccines to over 10 countries in Asia and South America. For more
information, please visit the Company's website at
www.sinovac.com
Safe Harbor Statement
This announcement may include certain statements that are not
descriptions of historical facts, but are forward-looking
statements. These statements are made under the "safe harbor"
provisions of the U.S. Private Securities Litigation Reform Act of
1995. These forward-looking statements can be identified by
terminology such as "will," "expects," "anticipates," "future,"
"intends," "plans," "believes," "estimates" and similar statements.
Forward-looking statements involve risks, uncertainties and other
factors that could cause actual results to differ materially from
those contained in any such statements.
Contact
Sinovac Biotech Ltd.
Helen
Yang
Tel: +86-10-8279-9871
Fax: +86-10-6296-6910
Email: ir@sinovac.com
ICR Inc.
Bill Zima
U.S: 1-646-308-1707
Email: william.zima@icrinc.com
View original
content:http://www.prnewswire.com/news-releases/sinovac-schedules-2017-annual-meeting-of-shareholders-300575977.html
SOURCE Sinovac Biotech Ltd.